share_log

D: Filing D

D: Filing D

D:发行公告
美股SEC公告 ·  2024/10/09 14:17

Moomoo AI 已提取核心信息

Clene Inc., a biopharmaceutical company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering. The filing, dated October 1, 2024, reports that the company has successfully raised $7,310,060 USD through the sale of securities. The offering, which did not last more than one year, included equity, options, warrants, and other rights to acquire additional securities. Clene Inc. has declined to disclose the issuer size in terms of revenue or aggregate net asset value. The company has also claimed an exemption under Rule 506(b) of the Securities Act. The filing lists several executive officers and directors, including President and CEO Robert Etherington, who signed the submission on October 9, 2024. No sales commissions or finders' fees were reported, and the proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters.
Clene Inc., a biopharmaceutical company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering. The filing, dated October 1, 2024, reports that the company has successfully raised $7,310,060 USD through the sale of securities. The offering, which did not last more than one year, included equity, options, warrants, and other rights to acquire additional securities. Clene Inc. has declined to disclose the issuer size in terms of revenue or aggregate net asset value. The company has also claimed an exemption under Rule 506(b) of the Securities Act. The filing lists several executive officers and directors, including President and CEO Robert Etherington, who signed the submission on October 9, 2024. No sales commissions or finders' fees were reported, and the proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters.
Clene Inc.,一家在特拉华州注册的生物制药公司,已向美国证券交易委员会提交了一份豁免证券发行通知表格D,表明进行了一项新的股本发行通知。该备案日期为2024年10月1日,报告称该公司通过出售证券成功筹集了7,310,060美元。该发行包括股本、期权、认购权和其他额外证券获取权利,但发行期未超过一年。Clene Inc.拒绝披露收入或总净资产价值的发行量。该公司还宣称根据证券法规第506(b)条规定获得豁免。备案中列出了几位高管和董事,包括总裁兼首席执行官Robert Etherington,他于2024年10月9日签署了提交文件。未报告销售佣金或中介费,发行所得款项不用于支付给上述高管、董事或推动者。
Clene Inc.,一家在特拉华州注册的生物制药公司,已向美国证券交易委员会提交了一份豁免证券发行通知表格D,表明进行了一项新的股本发行通知。该备案日期为2024年10月1日,报告称该公司通过出售证券成功筹集了7,310,060美元。该发行包括股本、期权、认购权和其他额外证券获取权利,但发行期未超过一年。Clene Inc.拒绝披露收入或总净资产价值的发行量。该公司还宣称根据证券法规第506(b)条规定获得豁免。备案中列出了几位高管和董事,包括总裁兼首席执行官Robert Etherington,他于2024年10月9日签署了提交文件。未报告销售佣金或中介费,发行所得款项不用于支付给上述高管、董事或推动者。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息